| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 11, 2005
Accepted on February 24, 2005
CNRS UMR 5160, Centre de Pharmacologie et Biotechnologie pour la Santé, Faculté de Pharmacie, BP 14491, 34093 Montpellier Cedex 5, France (D.B., S.A.R., B.N., S.P-R.); Medical Centre of Postgraduate Education, 01-813 Warsaw, Poland (A.G.); Division of Medicine, Guy's, King's and St Thomas' School of Medicine, King's College London, London United Kingdom SE1 9RT (J. P. B.); La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology-3, San Diego, CA 92121, USA (D.B., current address)
* To whom correspondence should be addressed. E-mail: sylvie.roux{at}ibph.pharma.univ-montp1.fr.
Human anti-thyroperoxidase (anti-TPO) autoantibodies (aAbs) are a major hallmark of autoimmune thyroid diseases. Their epitopes are discontinuous and mainly restricted to an immunodominant region (IDR) consisting of two overlapping regions (IDR/A and B). To shed light on the relationship between these regions, we first performed competitive studies using all available reference anti-TPO antibodies. Interestingly, we showed that human IDR/A- and B-specific anti-TPO aAbs recognized essentially the same regions on the TPO molecule. However, our data also indicated that IDR/A-specific human aAbs strongly recognized the region containing residues 599-617, whereas the IDR/B-specific bind to several regions as well as to region 599-617. Next, we scanned this key region to identify the residues involved in the immunodominant autoepitope. Using peptide spot technology together with competitive ELISA experiments, we demonstrated that (i) residues 604ETP-DL (609) play a major role in the anti-peptide P14 epitope, and (ii) IDR/A-specific human anti-TPO aAbs, either expressed as recombinant Fab or obtained from Graves' disease patients, specifically recognize the sequences 597FCGLPRLE (604) and 611TAIASRSV (618). All together our data emphasize that both the IDRs involve the same surface area on hTPO, but the differential usage of one or the other regions leads to different inhibition patterns in competitive experiments. In conclusion, our data help to resolve the long sought issue on the molecular immunology of the two IDRs on TPO, and provide new clues to design efficient peptides that may be part of a combinatorial treatment aiming at delaying development of autoimmune thyroiditis when used prophylactically.
This article has been cited by other articles:
 |
|
 |
|
  M. Dubska, J. P. Banga, D. Plochocka, G. Hoser, E. H. Kemp, B. J. Sutton, A. Gardas, and M. Gora Structural Insights into Autoreactive Determinants in Thyroid Peroxidase Composed of Discontinuous and Multiple Key Contact Amino Acid Residues Contributing to Epitopes Recognized by Patients' Autoantibodies Endocrinology, December 1, 2006; 147(12): 5995 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Rebuffat, D. Bresson, B. Nguyen, and S. Peraldi-Roux The key residues in the immunodominant region 353-363 of human thyroid peroxidase were identified Int. Immunol., July 1, 2006; 18(7): 1091 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Ng and A. W. C. Kung Induction of Autoimmune Thyroiditis and Hypothyroidism by Immunization of Immunoactive T Cell Epitope of Thyroid Peroxidase Endocrinology, June 1, 2006; 147(6): 3085 - 3092. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
